– USA, PA – Helius Medical Technologies (CSE: HSM), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce the appointment of Dr. Sackier as Chief Medical Officer (CMO). Dr. Sackier brings to his role as Chief Medical Officer more than 30 years of industry experience as an innovator and pioneer of new technologies. He is widely recognized as one of the leaders of the laparoscopic surgery revolution.
“I am honored to be part of such an important area of neurological science to help bring promising new technologies for patients seeking symptom relief. It represents one of the largest areas of unmet medical needs and I am proud to be a part of this growing company” said Jonathan Sackier, CMO of Helius.
“Jonathan Sackier is a highly regarded national health care expert who not only understands the challenges of health care today, but has experience bringing new technologies to market. As Helius plans to dramatically increase its clinical activity, we are very pleased to have Dr. Sackier not only as the Chair of our Scientific Advisory Board but also in the key positon of Chief Medical Officer” said Philippe Deschamps, CEO of Helius.
A trained surgeon, Dr. Sackier has helped build several companies including medical technology, research and product-design and medical contract sales organizations. He has also collaborated extensively with pharmaceutical and medical device technology partners including Bristol Myers, Pfizer, Karl Storz, Applied Medical, Stryker, Siemens, Bayer and Novartis.
Prior to joining Helius, Dr. Sackier served as Chairman of Adenosine Therapeutics, which became part of Clinical Data and then Forest Laboratories. He worked to develop and market the AESOP robot with Computer Motion, which successfully completed an IPO. He also founded Genethics, which patented and licensed amniotic stem cell technology.
As a Professor at George Washington University in Washington, DC, Dr. Sackier founded and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer. He is currently a pro bono Visiting Professor of Surgery at the Nuffield Department of Surgical Sciences at Oxford University.
Dr. Sackier sits on the board of directors of Kypha, Clinvue, and Hemoshear. He is Chairman of the Board of The Load Zero Foundation and a Trustee of First Star and previously chaired The Larry King Cardiac Foundation Board of Governors. He has also served as a board member of The American College of Surgeons Foundation, The Surgical Fellowship Foundation and Rex Bionics. He is the winner of London’s 2014 AIM Award for outstanding achievement for most successful growth market.
A keen pilot, Dr. Sackier advises the Aircraft Owners & Pilots Association (AOPA) on medical issues germane to pilots and authors the “Fly Well” column in AOPA Pilot magazine.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.